The Pathophysiology and Treatment of Osteoporosis

被引:247
作者
Drake, Matthew T. [1 ]
Clarke, Bart L. [1 ]
Lewiecki, E. Michael [2 ]
机构
[1] Mayo Clin, Coll Med, Div Endocrinol Diabet Metab & Nutr, Rochester, MN USA
[2] Univ New Mexico, Sch Med, New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM 87106 USA
关键词
aging; bisphosphonate; bone; bone mineral density; menopause; osteoporosis; BONE-MINERAL DENSITY; SEX STEROID-LEVELS; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; REPLACEMENT THERAPY; VERTEBRAL FRACTURE; TURNOVER MARKERS; RANDOMIZED-TRIAL; ZOLEDRONIC ACID;
D O I
10.1016/j.clinthera.2015.06.006
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Purpose: The objectives of this article are to review the pathophysiology of bone loss associated with aging and to review current pharmacologic approaches for the treatment of osteoporosis. Methods: A literature search with Pub Med was performed with the terms osteoporosis and pathophysiology and osteoporosis and treatment and limited to studies written in English that were published within the preceding 10 years. Given the large number of studies identified, we selectively reviewed those studies that contained primary data related to osteoporosis pathophysiology or osteoporosis pharmacologic treatments and references included within selected studies identified from abstract review. Findings: Published studies have consistently reported that osteoporosis in older adults is caused by an imbalance of bone resorption in excess of bone formation. The dominant factor leading to bone loss in older adults appears to be gonadal sex steroid deficiency, with multiple genetic and biochemical factors, such as vitamin D deficiency or hyperparathyroidism, that may accelerate bone loss. Conditions that adversely affect growth and development may limit development of peak bone mass and accelerate subsequent bone loss. Studies of bone microarchitecture have shown that trabecular bone loss begins in the third decade of life, before gonadal sex steroid deficiency develops, whereas cortical loss typically begins in the sixth decade, about the time of menopause in women and about the same age in men. Antiresorptive agents for the treatment of osteoporosis act primarily by limiting osteoclast activity, whereas osteoanabolic agents, such as teriparatide, act primarily by stimulating osteoblastic bone formation. Clinical investigation of new compounds for the treatment of osteoporosis is mainly directed to those that stimulate bone formation or differentially decrease bone resorption more than bone formation. Therapies for osteoporosis are associated with adverse effects, but in patients at high risk of fracture, the benefits generally far outweigh the risks. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:1837 / 1850
页数:14
相关论文
共 89 条
[1]
Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the framingham study [J].
Amin, S ;
Zhang, YQ ;
Sawin, DT ;
Evans, SR ;
Hannan, MT ;
Kiel, DP ;
Wilson, PWF ;
Felson, DT .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (12) :951-963
[2]
A potentially deleterious role of IGFBP-2 on bone density in aging men and women [J].
Amin, S ;
Riggs, BL ;
Atkinson, EJ ;
Oberg, AL ;
Melton, LJ ;
Khosla, S .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1075-1083
[3]
Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency [J].
Ammann, P ;
Rizzoli, R ;
Bonjour, JP ;
Bourrin, S ;
Meyer, JM ;
Vassalli, P ;
Garcia, I .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1699-1703
[4]
The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years [J].
Andrews, Elizabeth B. ;
Gilsenan, Alicia W. ;
Midkiff, Kirk ;
Sherrill, Beth ;
Wu, Yun ;
Mann, Beth H. ;
Masica, Daniel .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (12) :2429-2437
[5]
INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II - AGING AND BONE-DENSITY IN WOMEN [J].
BENNETT, AE ;
WAHNER, HW ;
RIGGS, BL ;
HINTZ, RL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 59 (04) :701-704
[6]
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[7]
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[8]
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[9]
The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension [J].
Bone, Henry G. ;
Chapurlat, Roland ;
Brandi, Maria-Luisa ;
Brown, Jacques P. ;
Czerwinski, Edward ;
Krieg, Marc-Antoine ;
Mellstrom, Dan ;
Radominski, Sebastiao C. ;
Reginster, Jean-Yves ;
Resch, Heinrich ;
Roman Ivorra, Jose A. ;
Roux, Christian ;
Vittinghoff, Eric ;
Daizadeh, Nadia S. ;
Wang, Andrea ;
Bradley, Michelle N. ;
Franchimont, Nathalie ;
Geller, Michelle L. ;
Wagman, Rachel B. ;
Cummings, Steven R. ;
Papapoulos, Socrates .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (11) :4483-4492
[10]
Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis [J].
Boonen, S ;
Mohan, S ;
Dequeker, J ;
Aerssens, J ;
Vanderschueren, D ;
Verbeke, G ;
Broos, P ;
Bouillon, R ;
Baylink, DJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) :2150-2158